Actinium Pharmaceuticals (ATNM) Return on Capital Employed (2011 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Return on Capital Employed of 61.84% for Q1 2026, up 1303.0% year-over-year from 4.41% in Q1 2025, and up 21.54% quarter-over-quarter from 78.81% in Q4 2025.
Actinium Pharmaceuticals (ATNM) Return on Capital Employed (2011 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Return on Capital Employed for 16 consecutive years, with 61.84% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1303.0% year-over-year to 61.84%; the TTM figure through Mar 2026 stood at 61.84% (up 1303.0% YoY), while the FY2025 annual figure was 64.3%, down 500.0% from the prior year.
- Return on Capital Employed grew to 61.84% in Q1 2026 per ATNM's latest filing, from 78.81% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.81% in Q3 2022 and bottomed at 78.81% in Q4 2025.
- Historically, Return on Capital Employed has averaged 55.96% across 5 years, with a median of 59.03% in 2024.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 3517 bps — and 2026, when it soared 1303 bps.
- Actinium Pharmaceuticals' Return on Capital Employed stood at 32.52% in 2022, then sank by 108 bps to 67.69% in 2023, then advanced by 13 bps to 59.03% in 2024, then slumped by 34 bps to 78.81% in 2025, then grew by 22 bps to 61.84% in 2026.
- Business Quant data shows ATNM's Return on Capital Employed at 61.84% in Q1 2026, 78.81% in Q4 2025, and 70.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 7.88% |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | 28.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.49% |
| Mar 31, 2026 | -61.84% |
| Dec 31, 2025 | -78.81% |
| Sep 30, 2025 | -70.78% |
| Jun 30, 2025 | -76.93% |
| Mar 31, 2025 | -74.87% |
| Dec 31, 2024 | -59.03% |
| Sep 30, 2024 | -57.47% |
| Jun 30, 2024 | -58.84% |
| Mar 31, 2024 | -64.99% |
| Dec 31, 2023 | -67.69% |
| Sep 30, 2023 | -61.96% |
| Jun 30, 2023 | -52.87% |
| Mar 31, 2023 | -40.42% |
| Dec 31, 2022 | -32.52% |
| Sep 30, 2022 | -27.81% |
| Jun 30, 2022 | -29.96% |
| Mar 31, 2022 | -34.50% |
| Dec 31, 2021 | -33.02% |
| Sep 30, 2021 | -29.09% |